爱康医疗(01789.HK):控股股东喜马拉亚配售5000万股公司股份 每股7.01港元
格隆汇9月10日丨爱康医疗(01789.HK)公布,公司董事会获公司一名控股股东喜马拉亚有限公司知会,其已于2019年9月9日交易时间之后与高盛(亚洲)有限责任公司订立配售协议。
据此,配售代理以每股7.01港元的价格向一家亚洲大型且高质量的投资管理公司独家配售由喜马拉亚有限公司持有的公司5000万股股份,相当于截至公告日期公司已发行股本约4.79%。
于紧随配售事项完成后,预计于2019年9月12日,喜马拉亚有限公司直接持有535,157,500股份,相当于截至公告日期已发行股份约51.27%。因此,喜马拉亚有限公司于配售事项后继续为公司的控股股东。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.